NYSEArca - Delayed Quote USD

ProShares Long Online/Short Stores ETF (CLIX)

40.69 -0.08 (-0.19%)
At close: April 18 at 9:36 AM EDT
Loading Chart for CLIX
DELL
  • Previous Close 40.77
  • Open 40.78
  • Bid 36.86 x 2200
  • Ask 44.68 x 1000
  • Day's Range 40.69 - 40.78
  • 52 Week Range 29.85 - 42.10
  • Volume 1,384
  • Avg. Volume 5,669
  • Net Assets 10.69M
  • NAV 40.80
  • PE Ratio (TTM) --
  • Yield 0.38%
  • YTD Daily Total Return 7.40%
  • Beta (5Y Monthly) 0.89
  • Expense Ratio (net) 0.65%

The fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the index. The index consists of long positions in the online retailers included in the ProShares Online Retail Index and short positions in the "bricks and mortar" retailers included in the Solactive-ProShares Bricks and Mortar Retail Store Index. The fund is non-diversified.

ProShares

Fund Family

Long-Short Equity

Fund Category

10.69M

Net Assets

2017-11-14

Inception Date

Performance Overview: CLIX

Trailing returns as of 4/17/2024. Category is Long-Short Equity.

YTD Return

CLIX
7.40%
Category
7.15%
 

1-Year Return

CLIX
30.01%
Category
16.52%
 

3-Year Return

CLIX
21.59%
Category
5.38%
 

People Also Watch

Holdings: CLIX

Top 8 Holdings (60.22% of Total Assets)

SymbolCompany% Assets
AMZN
Amazon.com, Inc. 20.78%
EBAY
eBay Inc. 9.00%
PDD
PDD Holdings Inc. 8.02%
WSM
Williams-Sonoma, Inc. 4.98%
W
Wayfair Inc. 4.53%
CVNA
Carvana Co. 4.52%
RVLV
Revolve Group, Inc. 4.29%
CPNG
Coupang, Inc. 4.10%

Sector Weightings

SectorCLIX
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%
Healthcare   0.00%

Related ETF News

Research Reports: CLIX

  • Analyst Report: CRISPR Therapeutics AG

    Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

    Rating
    Bullish
    Price Target
     
  • ENPH: Lowering target price to $116.00

    ENPHASE ENERGY INC has an Investment Rating of HOLD; a target price of $116.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.

    Rating
    Neutral
    Price Target
     
  • Analyst Report: Sunrun Inc.

    Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun’s partners and are owned by the company. Sunrun’s customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

    Rating
    Bullish
    Price Target
     
  • Analyst Report: Sunrun Inc.

    Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun’s partners and are owned by the company. Sunrun’s customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

    Rating
    Neutral
    Price Target
     

Related Tickers